Skye Bioscience, Inc. (SKYE)
USD 1.26
(-10.0%)
USD 1.26
(-10.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -37.64 Million USD | -93.23% |
| 2022 | -19.48 Million USD | -128.6% |
| 2021 | -8.52 Million USD | -29.9% |
| 2020 | -6.56 Million USD | -723.74% |
| 2019 | 1.05 Million USD | 105.48% |
| 2018 | -19.19 Million USD | -520.31% |
| 2017 | -3.09 Million USD | 2.64% |
| 2016 | -3.17 Million USD | 34.35% |
| 2015 | -4.84 Million USD | -77.06% |
| 2014 | -2.73 Million USD | -2170.85% |
| 2013 | -120.4 Thousand USD | -2770.28% |
| 2012 | 4509.00 USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -5.01 Million USD | -13.57% |
| 2024 Q2 | -7.9 Million USD | -57.44% |
| 2023 Q2 | -3.11 Million USD | 46.88% |
| 2023 Q1 | -5.85 Million USD | 40.78% |
| 2023 Q4 | -4.41 Million USD | 82.28% |
| 2023 FY | -37.64 Million USD | -93.23% |
| 2023 Q3 | -24.94 Million USD | -701.73% |
| 2022 Q4 | -9.89 Million USD | -196.84% |
| 2022 Q1 | -3.19 Million USD | -27.3% |
| 2022 Q2 | -3.41 Million USD | -6.89% |
| 2022 Q3 | -3.33 Million USD | 2.54% |
| 2022 FY | -19.48 Million USD | -128.6% |
| 2021 Q3 | -1.82 Million USD | 9.84% |
| 2021 Q4 | -2.51 Million USD | -37.7% |
| 2021 Q2 | -2.02 Million USD | 6.32% |
| 2021 Q1 | -2.16 Million USD | -43.83% |
| 2021 FY | -8.52 Million USD | -29.9% |
| 2020 FY | -6.56 Million USD | -723.74% |
| 2020 Q3 | -1.29 Million USD | 8.7% |
| 2020 Q2 | -1.42 Million USD | 39.35% |
| 2020 Q4 | -1.5 Million USD | -15.84% |
| 2020 Q1 | -2.34 Million USD | -148.26% |
| 2019 Q3 | -4.93 Million USD | -131.0% |
| 2019 FY | 1.05 Million USD | 105.48% |
| 2019 Q2 | 15.9 Million USD | 207.65% |
| 2019 Q4 | 4.85 Million USD | 198.4% |
| 2019 Q1 | -14.77 Million USD | -137.45% |
| 2018 FY | -19.19 Million USD | -520.31% |
| 2018 Q4 | -6.22 Million USD | -196.81% |
| 2018 Q3 | -2.09 Million USD | 21.25% |
| 2018 Q2 | -2.66 Million USD | 67.59% |
| 2018 Q1 | -8.21 Million USD | -1207.55% |
| 2017 FY | -3.09 Million USD | 2.64% |
| 2017 Q4 | -628.18 Thousand USD | -30.84% |
| 2017 Q1 | -1.28 Million USD | -14.53% |
| 2017 Q2 | -702.76 Thousand USD | 45.23% |
| 2017 Q3 | -480.13 Thousand USD | 31.68% |
| 2016 Q2 | 573.09 Thousand USD | 134.0% |
| 2016 FY | -3.17 Million USD | 34.35% |
| 2016 Q3 | -945.27 Thousand USD | -264.94% |
| 2016 Q4 | -1.12 Million USD | -18.53% |
| 2016 Q1 | -1.68 Million USD | -143.85% |
| 2015 FY | -4.84 Million USD | -77.06% |
| 2015 Q3 | -1.18 Million USD | 42.5% |
| 2015 Q4 | -691.18 Thousand USD | 41.56% |
| 2015 Q2 | -2.05 Million USD | -125.98% |
| 2015 Q1 | -910.22 Thousand USD | 46.54% |
| 2014 Q4 | -1.7 Million USD | -98.32% |
| 2014 Q3 | -858.51 Thousand USD | -11163.38% |
| 2014 Q2 | 7760.00 USD | 157.42% |
| 2014 Q1 | -13.51 Thousand USD | -473.31% |
| 2014 FY | -2.73 Million USD | -2170.85% |
| 2013 Q1 | 2069.00 USD | 1193.13% |
| 2013 Q2 | -712.00 USD | -134.41% |
| 2013 Q3 | -5169.00 USD | -625.98% |
| 2013 Q4 | 3620.00 USD | 170.03% |
| 2013 FY | -120.4 Thousand USD | -2770.28% |
| 2012 FY | 4509.00 USD | 0.0% |
| 2012 Q1 | -381.00 USD | 0.0% |
| 2012 Q2 | 55.00 USD | 114.44% |
| 2012 Q3 | 4656.00 USD | 8365.45% |
| 2012 Q4 | 160.00 USD | -96.56% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 52.97 Million USD | 171.056% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -5852.62% |
| Nascent Biotech, Inc. | -2.08 Million USD | -1703.186% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -8960.574% |
| Qrons Inc. | -789.34 Thousand USD | -4669.105% |
| Rebus Holdings, Inc. | -1.02 Million USD | -3590.665% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 157.797% |
| Adynxx, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 39.864% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -137.186% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -439.105% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -2718.924% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 49.782% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -472.448% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -13669.023% |
| SQZ Biotechnologies Company | -79.46 Million USD | 52.627% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -1201.51% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -1967.795% |
| Mesoblast Limited | -87.95 Million USD | 57.2% |
| Marizyme, Inc. | -65.34 Million USD | 42.392% |
| Genus plc | 7.9 Million USD | 576.516% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -245.627% |
| Pharming Group N.V. | -10.54 Million USD | -256.89% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -1634.931% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -914.62% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -325.653% |
| ContraFect Corporation | -65.15 Million USD | 42.221% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -670.452% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -2079.205% |
| IMV Inc. | -36.48 Million USD | -3.177% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -367.075% |
| MultiCell Technologies, Inc. | -380.07 USD | -9904597.556% |
| ONE Bio Corp. | 8.67 Million USD | 533.865% |
| Accustem Sciences Inc. | -3.74 Million USD | -904.82% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 27.175% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -2870.861% |
| Q BioMed Inc. | -2.05 Million USD | -1734.458% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -908.432% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -1481.136% |
| Biomind Labs Inc. | -1.21 Million USD | -3000.074% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 36.97% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -1113.656% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -376.33% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -1831.246% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -251267.415% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -547.123% |
| GB Sciences, Inc. | -1.36 Million USD | -2664.59% |
| Alpha Cognition Inc. | -13.77 Million USD | -173.332% |
| HST Global, Inc. | -146.21 Thousand USD | -25647.065% |
| CSL Limited | 2.64 Billion USD | 101.425% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -2045.282% |
| Halberd Corporation | -79.67 Thousand USD | -47147.332% |
| Enzolytics Inc. | -2.17 Million USD | -1629.338% |
| Agentix Corp. | -1.37 Million USD | -2639.374% |
| Resverlogix Corp. | -3.61 Million USD | -942.792% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -1086.995% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 87.241% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 38513.045% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 643.639% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -847.517% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -1143.989% |
| AVAX Technologies, Inc. | -6.41 Million USD | -486.948% |
| Zenith Capital Corp. | -10.59 Million USD | -255.274% |
| Genscript Biotech Corporation | -95.47 Million USD | 60.572% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -161868.781% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -807.992% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -62183.925% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -1777.438% |
| Kadimastem Ltd | -3.3 Million USD | -1038.199% |
| Helix BioMedix, Inc. | -1.05 Million USD | -3464.655% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -885.724% |
| BioStem Technologies, Inc. | -8.48 Million USD | -343.768% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -8429.096% |
| LadRx Corporation | 400.44 Thousand USD | 9500.785% |
| Cell Source, Inc. | -5.32 Million USD | -607.448% |
| Regen BioPharma, Inc. | 1.02 Million USD | 3778.016% |
| Regen BioPharma, Inc. | 1.02 Million USD | 3778.016% |
| NovAccess Global Inc. | -4.76 Million USD | -689.333% |
| Affymax, Inc. | -14.42 Million USD | -160.987% |
| Itoco Inc. | -1.86 Million USD | -1914.173% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -747.372% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -2155.529% |
| Mobile Lads Corp. | -2.26 Million USD | -1563.276% |
| CytoDyn Inc. | -49.84 Million USD | 24.47% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -47531.729% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -16401.678% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -3898.261% |
| SYBLEU INC | -180.3 Thousand USD | -20778.507% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -2234.217% |
| International Stem Cell Corporation | -131 Thousand USD | -28636.476% |
| Bioxytran, Inc. | -4.28 Million USD | -779.551% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -69263.178% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -1387.791% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 21.691% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -1680.737% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -4720.772% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -1088.282% |
| Neutra Corp. | -233.46 Thousand USD | -16024.38% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -85.525% |
| PureTech Health plc | -65.69 Million USD | 42.699% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | -77.014% |
| IXICO plc | -1.17 Million USD | -3095.652% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -279.216% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 34.104% |
| CSL Limited | 2.64 Billion USD | 101.425% |
| Cellectis S.A. | -103.17 Million USD | 63.513% |